Sort by

Send to

Choose Destination

Links from PubMed

Items: 2


Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program.

Houghton PJ, Lock R, Carol H, Morton CL, Phelps D, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Maris JM, Wozniak AW, Gu Y, Wilson WR, Smith MA.

Pediatr Blood Cancer. 2011 Sep;57(3):443-53. doi: 10.1002/pbc.22921. Epub 2010 Dec 27.


Design of optimized hypoxia-activated prodrugs using pharmacokinetic/pharmacodynamic modeling.

Foehrenbacher A, Secomb TW, Wilson WR, Hicks KO.

Front Oncol. 2013 Dec 27;3:314. doi: 10.3389/fonc.2013.00314. Review.

Supplemental Content

Support Center